Siegel C - Search Results

1

Treat-to-Target: The Era of Targeted Immunosuppressive Agents in IBD Management.

Marino D, Singh S, Hou J, Siegel C, Melmed G, Shah SA. Marino D, et al. Among authors: siegel c. R I Med J (2013). 2022 Nov 1;105(9):25-29. R I Med J (2013). 2022. PMID: 36300960 Free article.

2

Controversies in ulcerative colitis: a survey comparing decision making of experts versus community gastroenterologists.

Spiegel BM, Ho W, Esrailian E, Targan S, Higgins PD, Siegel CA, Dubinsky M, Melmed GY. Spiegel BM, et al. Clin Gastroenterol Hepatol. 2009 Feb;7(2):168-74, 174.e1. doi: 10.1016/j.cgh.2008.08.029. Epub 2008 Sep 4. Clin Gastroenterol Hepatol. 2009. PMID: 18952199 Free PMC article.

3

Improving quality of care in IBD: a STEEEP challenge.

Siegel CA, Melmed GY, Ullman TA. Siegel CA, et al. Inflamm Bowel Dis. 2010 Jan;16(1):134-6. doi: 10.1002/ibd.21024. Inflamm Bowel Dis. 2010. PMID: 19637384 No abstract available.

4

Setting priorities for comparative effectiveness research in inflammatory bowel disease: results of an international provider survey, expert RAND panel, and patient focus groups.

Cheifetz AS, Melmed GY, Spiegel B, Talley J, Devlin SM, Raffals L, Irving PM, Jones J, Kaplan GG, Kozuch P, Sparrow M, Velayos F, Baidoo L, Bressler B, Siegel CA. Cheifetz AS, et al. Among authors: siegel ca. Inflamm Bowel Dis. 2012 Dec;18(12):2294-300. doi: 10.1002/ibd.22920. Epub 2012 Feb 15. Inflamm Bowel Dis. 2012. PMID: 22337359

5

A quality improvement project significantly increased the vaccination rate for immunosuppressed patients with IBD.

Parker S, Chambers White L, Spangler C, Rosenblum J, Sweeney S, Homan E, Bensen SP, Levy LC, Dragnev MC, Moskalenko-Locke K, Rich P, Siegel CA. Parker S, et al. Among authors: siegel ca. Inflamm Bowel Dis. 2013 Aug;19(9):1809-14. doi: 10.1097/MIB.0b013e31828c8512. Inflamm Bowel Dis. 2013. PMID: 23714677

6

Translating improved quality of care into an improved quality of life for patients with inflammatory bowel disease.

Siegel CA, Allen JI, Melmed GY. Siegel CA, et al. Clin Gastroenterol Hepatol. 2013 Aug;11(8):908-12. doi: 10.1016/j.cgh.2013.05.027. Epub 2013 Jun 5. Clin Gastroenterol Hepatol. 2013. PMID: 23747710 Review.

7

Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel disease.

Dulai PS, Siegel CA, Dubinsky MC. Dulai PS, et al. Among authors: siegel ca. Inflamm Bowel Dis. 2013 Dec;19(13):2927-36. doi: 10.1097/MIB.0b013e31829aad16. Inflamm Bowel Dis. 2013. PMID: 23867874 Free PMC article. Review.

8

Quality improvement in inflammatory bowel disease.

Melmed GY, Siegel CA. Melmed GY, et al. Gastroenterol Hepatol (N Y). 2013 May;9(5):286-92. Gastroenterol Hepatol (N Y). 2013. PMID: 23943663 Free PMC article.

9

The risk of malignancy associated with the use of biological agents in patients with inflammatory bowel disease.

Dulai PS, Siegel CA. Dulai PS, et al. Gastroenterol Clin North Am. 2014 Sep;43(3):525-41. doi: 10.1016/j.gtc.2014.05.010. Epub 2014 Jun 13. Gastroenterol Clin North Am. 2014. PMID: 25110257 Review.

10

Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis.

Hazlewood GS, Rezaie A, Borman M, Panaccione R, Ghosh S, Seow CH, Kuenzig E, Tomlinson G, Siegel CA, Melmed GY, Kaplan GG. Hazlewood GS, et al. Gastroenterology. 2015 Feb;148(2):344-54.e5; quiz e14-5. doi: 10.1053/j.gastro.2014.10.011. Epub 2014 Oct 16. Gastroenterology. 2015. PMID: 25448924

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

873 results

Search Page

Filters